Startseite>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Methyltransferase>>BI-9321 trihydrochloride

BI-9321 trihydrochloride

Katalog-Nr.GC39663

BI-9321-Trihydrochlorid ist ein potenter, selektiver und zellaktiver Nuklearrezeptor-bindender Antagonist der SET-DomÄne 3 (NSD3)-PWWP1-DomÄne mit einem Kd-Wert von 166 nM. BI-9321-Trihydrochlorid ist gegen NSD2-PWWP1 und NSD3-PWWP2 inaktiv. BI-9321-Trihydrochlorid unterbricht spezifisch Histon-Wechselwirkungen der NSD3-PWWP1-DomÄne mit einem IC50 von 1,2 μM in U2OS-Zellen.

Products are for research use only. Not for human use. We do not sell to patients.

BI-9321 trihydrochloride Chemische Struktur

Cas No.: 2387510-87-2

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
133,00 $
Auf Lager
5mg
121,00 $
Auf Lager
10mg
213,00 $
Auf Lager
25mg
417,00 $
Auf Lager
50mg
705,00 $
Auf Lager
100mg
1.112,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com


Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

BI-9321 trihydrochloride is a potent, selective and cellular active nuclear receptor-binding SET domain 3 (NSD3)-PWWP1 domain antagonist with a Kd value of 166 nM. BI-9321 trihydrochloride is inactive against NSD2-PWWP1 and NSD3-PWWP2. BI-9321 trihydrochloride specifically disrupts histone interactions of the NSD3-PWWP1 domain with an IC50 of 1.2 μM in U2OS cells[1].

[1]. BÖttcher J, et al. Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3. Nat Chem Biol. 2019 Aug;15(8):822-829.

Bewertungen

Review for BI-9321 trihydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BI-9321 trihydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.